1. Home
  2. WVE vs THQ Comparison

WVE vs THQ Comparison

Compare WVE & THQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Wave Life Sciences Ltd.

WVE

Wave Life Sciences Ltd.

N/A

Current Price

$3.88

Market Cap

744.8M

Sector

Health Care

ML Signal

N/A

Logo abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

THQ

abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

N/A

Current Price

$17.85

Market Cap

784.0M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
WVE
THQ
Founded
2012
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance Companies
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
744.8M
784.0M
IPO Year
2015
N/A

Fundamental Metrics

Financial Performance
Metric
WVE
THQ
Price
$3.88
$17.85
Analyst Decision
Strong Buy
Analyst Count
18
0
Target Price
★ $18.53
N/A
AVG Volume (30 Days)
★ 2.8M
101.4K
Earning Date
11-09-2026
01-01-0001
Dividend Yield
N/A
★ 7.53%
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
★ $3,704,000.00
N/A
Revenue This Year
$20.53
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 149.43
N/A
52 Week Low
$3.56
$16.28
52 Week High
$21.73
$20.39

Technical Indicators

Market Signals
Indicator
WVE
THQ
Relative Strength Index (RSI) 36.57 34.78
Support Level N/A $18.02
Resistance Level $6.33 $18.50
Average True Range (ATR) 0.21 0.26
MACD -0.02 -0.09
Stochastic Oscillator 38.99 21.12

Price Performance

Historical Comparison
WVE
THQ

About WVE Wave Life Sciences Ltd.

WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

About THQ abrdn Healthcare Opportunities Fund Shares of Beneficial Interest

abrdn Healthcare Opportunities Fund is a non-diversified closed-end fund in the United States. Its investment objective is to seek current income and long-term capital appreciation through investments in U.S. and non-U.S. companies. The fund invests in equity and debt securities of public and private healthcare companies believed by the Fund's Adviser to have potential for above-average growth, and may invest in private companies and other restricted securities, including private investments in public equity and venture capital investments, provided these securities comprise 10% or less of Managed Assets.

Share on Social Networks: